Cargando…

Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine

Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine-encoding CAG expansion in the huntingtin gene. Iron accumulates in the brains of HD patients and mouse disease models. However, the cellular and subcellular sites of iron accumulation, as well as signific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jianfang, Marks, Eileen, Lai, Barry, Zhang, Zhaojie, Duce, James A., Lam, Linh Q., Volitakis, Irene, Bush, Ashley I., Hersch, Steven, Fox, Jonathan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795666/ https://www.ncbi.nlm.nih.gov/pubmed/24146952 http://dx.doi.org/10.1371/journal.pone.0077023

Ejemplares similares

Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
por: Chen, Jianfang, et al.
Publicado: (2013)

Mechanisms of Copper Ion Mediated Huntington's Disease Progression
por: Fox, Jonathan H., et al.
Publicado: (2007)

Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease
por: Berggren, Kiersten L., et al.
Publicado: (2015)

Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson’s disease
por: Ayton, Scott, et al.
Publicado: (2014)

Baicalin and deferoxamine alleviate iron accumulation in different brain regions of Parkinson's disease rats★
por: Xiong, Pei, et al.
Publicado: (2012)

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage
por: Li, Zhe, et al.
Publicado: (2022)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Deferoxamine inhibition of malaria is independent of host iron status
Publicado: (1988)

The iron chelator deferoxamine decreases myeloma cell survival
por: Yang, Feifei, et al.
Publicado: (2021)

β-Amyloid Precursor Protein Does Not Possess Ferroxidase Activity but Does Stabilize the Cell Surface Ferrous Iron Exporter Ferroportin
por: Wong, Bruce X., et al.
Publicado: (2014)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Testing of the siderophore deferoxamine amended in hydrogels for the cleaning of iron corrosion
por: Cuvillier, Luana, et al.
Publicado: (2023)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Re: “Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats,” and “Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model”
por: Mazaheri, Safoora, et al.
Publicado: (2014)

Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice
por: Yan, Hong-Fa, et al.
Publicado: (2018)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats
por: Nematbakhsh, Mehdi, et al.
Publicado: (2013)

Comparison Between Hesperidin, Coumarin, and Deferoxamine Iron Chelation and Antioxidant Activity Against Excessive Iron in the Iron Overloaded Mice
por: Aalikhani, Mahdi, et al.
Publicado: (2022)

Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
por: Ikeda, Yasumasa, et al.
Publicado: (2014)

Deferoxamine regulates neuroinflammation and iron homeostasis in a mouse model of postoperative cognitive dysfunction
por: Li, Yuping, et al.
Publicado: (2016)

Ameliorating Iron Overload in Intestinal Tissue of Adult Male Rats: Quercetin vs Deferoxamine
por: El-Sheikh, Arwa A., et al.
Publicado: (2018)

PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats
por: Xu, Jiake, et al.
Publicado: (2020)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
por: Lazaridou, Maria, et al.
Publicado: (2020)

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats
por: Feng, Yunfei, et al.
Publicado: (2023)

Characterization of Striatal Neuronal Loss and Atrophy in the R6/2 Mouse Model of Huntington’s Disease
por: Dodds, Lindsay, et al.
Publicado: (2014)

Re: Protective Role of Silymarin and Deferoxamine against Iron Dextran - Induced Renal Iron Deposition in Male Rats
por: Baradaran, Azar, et al.
Publicado: (2014)

Comment on: The Protective Role of Silymarin and Deferoxamine Against Iron Dextran-Induced Renal Iron Deposition in Male Rats
por: Baradaran, Azar
Publicado: (2013)

Comparison of apical and basolateral Cu treatment for iron-related gene regulation during deferoxamine induced iron deficiency
por: Evcan, Ezgi, et al.
Publicado: (2022)

Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model
por: Navidi-Shishaone, Mitra, et al.
Publicado: (2014)

Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?
por: Bray, Lisa, et al.
Publicado: (2019)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Physiological and Transcriptome Analyses Revealed the Mechanism by Which Deferoxamine Promotes Iron Absorption in Cinnamomum camphora
por: Kong, Wei-Liang, et al.
Publicado: (2022)

Renal iron accumulation occurs in lupus nephritis and iron chelation delays the onset of albuminuria
por: Marks, Eileen S., et al.
Publicado: (2017)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020)

Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism
por: Chen, Chunli, et al.
Publicado: (2019)

Deferoxamine retinopathy: spectral domain-optical coherence tomography findings
por: Wu, Cheng-Hsiu, et al.
Publicado: (2014)

A Novel Star Like Eight-Arm Polyethylene Glycol-Deferoxamine Conjugate for Iron Overload Therapy
por: Yu, Bohong, et al.
Publicado: (2020)

Neuroprotective effect of deferoxamine on erastin-induced ferroptosis in primary cortical neurons
por: Zhang, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8vd6sd34m38li0s2heu360bvh6